May 25th 2022 10:00 AM EDT | 3:00 PM GMT
Driving long-term value from biotech platform deals
Loading...
One of the fastest growing investment areas in biotech is around enabling technologies and platforms, such as gene and cell therapies, antibody-drug conjugates(ADCs), RNA technologies and AI/ML applications. And with good reason, as a single platform deal has the potential to fuel a multitude of life-saving treatments.
In this panel, Mike Ward speaks with industry leaders from big pharma and Adaptimmune to discuss learnings from their technology partnerships and examine what factors help drive successful deals and long-term portfolio value.
In this panel, Mike Ward speaks with industry leaders from big pharma and Adaptimmune to discuss learnings from their technology partnerships and examine what factors help drive successful deals and long-term portfolio value.
Takeaways from this panel will include:
-
What are pharma companies looking for in a technology platform partner?
-
How can biotechs position their platforms to be most attractive to potential suitors?
-
What types of emerging platform providers should pharma keep an eye on? Where is the white space and areas to maximize ROI?
-
What are some of the trends in relationship management, and how can you best set expectations on both sides?
Panelist information
Michael Ward
Global Head of Thought Leadership, Life Sciences and Healthcare
Clarivate
Clarivate
Helen Tayton-Martin
Chief Business Officer & Co-Founder AdaptImmune
Kendra Rose, PhD, MBA
VP and Head of New Platforms,
Ophthalmology and Hemophilia
Bayer
Ophthalmology and Hemophilia
Bayer
Faical Miyara, PhD
Head of Global Partnering Oncology Ipsen
Fill in the form below to register now
